Laurent Debussche

Sanofi R&D
Vitry-sur-seine, 94400, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients.

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients.

Journal: iScience

Published: July 24, 2024

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 21, 2023

Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss.

Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss.

Journal: Cancer research communications

Published: July 29, 2022

Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 20, 2022

YAP1 is essential for malignant mesothelioma tumor maintenance.

YAP1 is essential for malignant mesothelioma tumor maintenance.

Journal: BMC cancer

Published: January 12, 2022

KRAS G12C fragment screening renders new binding pockets.

KRAS G12C fragment screening renders new binding pockets.

Journal: Small GTPases

Published: September 24, 2021

Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition.

Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition.

Journal: SLAS discovery : advancing life sciences R & D

Published: April 26, 2021

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Journal: Molecular cancer therapeutics

Published: May 08, 2020

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Journal: Molecular cancer therapeutics

Published: July 18, 2017

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.

Journal: Oncogene

Published: November 24, 2016

Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53.

Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53.

Journal: Biochimica et biophysica acta

Published: February 10, 2016

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.

Journal: Oncotarget

Published: January 08, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026